- AstraZeneca’s core EPS for 1Q exceeded estimates with actual result standing at $2.06 per share, against an estimated $1.89.
- The revenue for the first quarter totalled to $12.68 billion, also surpassing the estimated amount of $11.82 billion.
- Research & Development (R&D) expenses surged to $2.78 billion, somewhat eclipsing the estimate of $2.4 billion.
- Similarly, the Selling, General & Administrative (SG&A) expense reached $4.5 billion, slightly more than the anticipated $4.32 billion.
- The Company has opted to maintain its Total Revenue and Core EPS guidance for Financial Year (FY) 2024 at Constant Exchange Rate (CER), which is determined by average foreign exchange rates through 2023.
- Forecasts for FY 2024 project that if foreign exchange rates from April 2024 to December 2024 align with averages witnessed in March 2024, Total Revenue is expected to experience low single-digit adverse impact. Core EPS is forecasted to see a mid single-digit adverse effect, which is a slight increase from the previous low single-digit prediction.
- Of the surveyed market participants, 25 have rated the stock as a buy, 7 hold, and 1 sell.
`
A look at AstraZeneca PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 4 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Analysts have provided insights into the long-term outlook for AstraZeneca PLC, a holding company that specializes in pharmaceutical and medical products. Based on Smartkarma Smart Scores, AstraZeneca received a promising score for growth and momentum, indicating positive prospects in these areas. With a focus on eight therapeutic areas including oncology and cardiovascular, the company’s future expansion and market performance appear to be on a solid trajectory.
Although AstraZeneca scored lower in terms of value and resilience, its higher scores in growth and momentum suggest potential for long-term success. As a company that researches, manufactures, and sells pharmaceutical products, AstraZeneca’s strategic focus on key therapeutic areas positions it well for future developments and market competitiveness.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
